NIKA.US Nika BioTechnology Inc
- Market cap
- USD 369M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NIKA.US undervalued?
Graham numberThe Graham number of Nika BioTechnology Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Nika BioTechnology Inc fundamental analysis
No fundamental analysis for Nika BioTechnology Inc yet.
Nika BioTechnology Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Nika BioTechnology Inc
Nika Pharmaceuticals, Inc. engages in the development and distribution pharmaceutical products for dietary supplements and antiviral drugs in the United States. The company offers ITV-1, TNG, physiolong, carotilen, fructin, dry boza, anthocylen C, hypocholestin, biodetoxin, silymaron, and solamentum products. The company was formerly known as Centennial Growth Equities Inc. and changed its name to Nika Pharmaceuticals, Inc. in May 2022. Nika Pharmaceuticals, Inc. was incorpo…
Full company profileNika BioTechnology Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Nika BioTechnology Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | - | 0.00 | 85.2K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | - | - | - | 85.2K | - | - | - | - | - |
| Operating Income | -48.6K | -48.9K | -33.4K | -6.50K | -8.91K | -14.7K | -3.18M | -64.8K | -95.8K | -76.4K | -61.4K |
| EBITDA | -48.6K | -48.9K | -33.4K | -6.50K | -6.50K | -14.7K | -3.18M | -64.8K | -95.8K | -76.4K | -61.4K |
| Net Income | -45.3K | -49.0K | -33.8K | -6.65K | -8.91K | -14.7K | -3.18M | -64.8K | -95.8K | -76.4K | -61.4K |
| EPS | -0.02 | -0.02 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 120.00 | 2.49K | 66.00 | 22.00 | 1.61K | 399.00 | 864.00 | 19.6K | 17.9K | 21.0K | 5.31K |
| Total Liabilities | 108K | 159K | 176K | 182K | 10.5K | 24.0K | 18.2K | 102K | 239K | 319K | 349K |
| Shareholders' Equity | -108K | -157K | -176K | -182K | -8.91K | -23.6K | -17.3K | -82.1K | -221K | -298K | -344K |
| Cash & Short-term Investments | 120.00 | 2.49K | 66.00 | 22.00 | 1.61K | 399.00 | 864.00 | 19.6K | 2.08K | 1.89K | 352.00 |
| Total Debt | 72.0K | 98.1K | - | - | 10.5K | 24.0K | 18.2K | 102K | 239K | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | - | - | - | - | -8.91K | -14.7K | -33.7K | -64.8K | -155K | -79.7K | -42.6K |
| Capital Expenditure | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | - | - | - | -8.91K | -14.7K | -33.7K | -64.8K | -139K | -79.7K | -42.6K |
| Ratios | |||||||||||
| ROA | -37,786.7% | -1,969.2% | -51,142.4% | -30,213.6% | -552.9% | -3,687.2% | -368,485.5% | -330.8% | -534.1% | -363.9% | -1,157.2% |
| Net Profit Margin | - | - | - | - | - | -17.3% | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Nika BioTechnology Inc dividends
Nika BioTechnology Inc has not paid dividends in the last 6 fiscal years.
Last stock split: 1:15 on Jul 21, 2021.
Who owns Nika BioTechnology Inc
- Insiders 85.78%
- Institutions 0.00%
- Public & others 14.22%
- Shares outstanding 1.05B
- Free float 288M
Nika BioTechnology Inc company profile
- Company name
- Nika BioTechnology Inc
- Ticker
- NIKA.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- 2269 Merrimack Valley Avenue, Henderson, NV, United States, 89044
- Phone
- 702 326 3615
- Website
- nikapharmaceuticals.com
About Nika BioTechnology Inc
Nika Pharmaceuticals, Inc. engages in the development and distribution pharmaceutical products for dietary supplements and antiviral drugs in the United States. The company offers ITV-1, TNG, physiolong, carotilen, fructin, dry boza, anthocylen C, hypocholestin, biodetoxin, silymaron, and solamentum products. The company was formerly known as Centennial Growth Equities Inc. and changed its name to Nika Pharmaceuticals, Inc. in May 2022. Nika Pharmaceuticals, Inc. was incorporated in 2000 and is based in Henderson, Nevada.
Nika BioTechnology Inc management
2- Mr. Dimitar Slavchev SavovPresident, CEO, CFO & Director · born 1958
- Mr. Clifford RedekopSecretary & Director · born 1949